Loading...

International Stem Cell

OTCPK:ISCO
Snowflake Description

Overvalued with concerning outlook.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
ISCO
OTCPK
$7M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

International Stem Cell Corporation focuses on the development of therapeutic and biomedical products worldwide. The last earnings update was 8 days ago. More info.


Add to Portfolio Compare Print
  • International Stem Cell has significant price volatility in the past 3 months.
ISCO Share Price and Events
7 Day Returns
-18.6%
OTCPK:ISCO
1%
US Biotechs
0.2%
US Market
1 Year Returns
-43.4%
OTCPK:ISCO
-4.6%
US Biotechs
2.9%
US Market
ISCO Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
International Stem Cell (ISCO) -18.6% -22.3% -40% -43.4% -60.5% -96%
US Biotechs 1% -0% -3.2% -4.6% 3.8% 9.7%
US Market 0.2% -1.6% 2.4% 2.9% 36.1% 41%
1 Year Return vs Industry and Market
  • ISCO underperformed the Biotechs industry which returned -4.6% over the past year.
  • ISCO underperformed the Market in United States of America which returned 2.9% over the past year.
Price Volatility
ISCO
Industry
5yr Volatility vs Market

Value

 Is International Stem Cell undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for International Stem Cell. This is due to cash flow or dividend data being unavailable. The share price is $0.9.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for International Stem Cell's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are International Stem Cell's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
OTCPK:ISCO PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $-0.33
OTCPK:ISCO Share Price ** OTCPK (2019-05-22) in USD $0.9
United States of America Biotechs Industry PE Ratio Median Figure of 35 Publicly-Listed Biotechs Companies 19.23x
United States of America Market PE Ratio Median Figure of 3,085 Publicly-Listed Companies 17.79x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of International Stem Cell.

OTCPK:ISCO PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= OTCPK:ISCO Share Price ÷ EPS (both in USD)

= 0.9 ÷ -0.33

-2.73x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • International Stem Cell is loss making, we can't compare its value to the US Biotechs industry average.
  • International Stem Cell is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does International Stem Cell's expected growth come at a high price?
Raw Data
OTCPK:ISCO PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -2.73x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
-71%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 28 Publicly-Listed Biotechs Companies 1.26x
United States of America Market PEG Ratio Median Figure of 2,123 Publicly-Listed Companies 1.54x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for International Stem Cell, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on International Stem Cell's assets?
Raw Data
OTCPK:ISCO PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $0.42
OTCPK:ISCO Share Price * OTCPK (2019-05-22) in USD $0.9
United States of America Biotechs Industry PB Ratio Median Figure of 414 Publicly-Listed Biotechs Companies 3.35x
United States of America Market PB Ratio Median Figure of 5,201 Publicly-Listed Companies 1.84x
OTCPK:ISCO PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= OTCPK:ISCO Share Price ÷ Book Value per Share (both in USD)

= 0.9 ÷ 0.42

2.13x

* Primary Listing of International Stem Cell.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • International Stem Cell is good value based on assets compared to the US Biotechs industry average.
X
Value checks
We assess International Stem Cell's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. International Stem Cell has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is International Stem Cell expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-71%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is International Stem Cell expected to grow at an attractive rate?
  • Unable to compare International Stem Cell's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare International Stem Cell's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.
  • International Stem Cell's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
OTCPK:ISCO Future Growth Rates Data Sources
Data Point Source Value (per year)
OTCPK:ISCO Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts -71%
OTCPK:ISCO Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 15%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 22.6%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 17.7%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.7%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
OTCPK:ISCO Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
OTCPK:ISCO Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2020-12-31 14 -7 1
2019-12-31 13 -3 1
OTCPK:ISCO Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 11 -1 -2
2018-12-31 11 -1 -2
2018-09-30 11 -2 -2
2018-06-30 9 -1 -5
2018-03-31 8 -2 -4
2017-12-31 7 -2 -6
2017-09-30 7 -3 -3
2017-06-30 7 -3 0
2017-03-31 8 -3 10
2016-12-31 7 -4 -1
2016-09-30 7 -4 -5
2016-06-30 8 -4 -6

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • International Stem Cell is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • International Stem Cell's revenue is expected to grow by 15% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
OTCPK:ISCO Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from International Stem Cell Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:ISCO Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2020-12-31 -0.88 -0.88 -0.88 1.00
2019-12-31 -0.36 -0.36 -0.36 1.00
OTCPK:ISCO Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 -0.33
2018-12-31 -0.33
2018-09-30 -0.43
2018-06-30 -0.91
2018-03-31 -0.81
2017-12-31 -1.46
2017-09-30 -0.64
2017-06-30 0.02
2017-03-31 3.00
2016-12-31 -0.34
2016-09-30 -1.65
2016-06-30 -2.24

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if International Stem Cell will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess International Stem Cell's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
International Stem Cell has a total score of 1/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has International Stem Cell performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare International Stem Cell's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • International Stem Cell does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare International Stem Cell's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare International Stem Cell's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
International Stem Cell's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from International Stem Cell Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:ISCO Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 10.67 -2.21 7.84 1.92
2018-12-31 11.09 -2.13 7.81 2.07
2018-09-30 10.71 -2.49 7.56 2.13
2018-06-30 9.36 -4.78 7.30 2.19
2018-03-31 8.08 -3.82 7.09 2.48
2017-12-31 7.46 -6.07 6.79 2.31
2017-09-30 7.30 -2.52 6.83 2.46
2017-06-30 7.40 0.06 6.93 2.47
2017-03-31 7.55 10.41 7.17 2.60
2016-12-31 7.17 -1.08 7.20 2.54
2016-09-30 7.45 -4.77 7.42 2.32
2016-06-30 7.65 -5.73 7.47 2.16
2016-03-31 7.55 -15.92 7.28 1.88
2015-12-31 7.55 -2.64 7.46 2.42
2015-09-30 7.39 -5.70 7.44 3.60
2015-06-30 7.22 -7.20 7.76 4.56
2015-03-31 6.99 -12.33 7.99 5.55
2014-12-31 7.02 -12.48 8.27 5.39
2014-09-30 6.94 -10.65 8.81 4.38
2014-06-30 6.64 -12.41 8.72 3.92
2014-03-31 6.51 -10.20 9.08 3.48
2013-12-31 6.15 -10.48 8.72 3.25
2013-09-30 5.66 -10.31 8.70 3.52
2013-06-30 5.18 -8.50 8.76 3.49
2013-03-31 4.78 -8.92 8.78 3.31
2012-12-31 4.57 -11.34 9.31 3.60
2012-09-30 4.38 -11.47 9.20 3.87
2012-06-30 4.04 -12.15 9.62 4.10

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if International Stem Cell has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if International Stem Cell has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if International Stem Cell improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess International Stem Cell's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
International Stem Cell has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is International Stem Cell's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up International Stem Cell's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • International Stem Cell's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • International Stem Cell's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of International Stem Cell's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 1.5x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from International Stem Cell Company Filings, last reported 1 month ago.

OTCPK:ISCO Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 3.19 2.31 0.62
2018-12-31 2.54 2.05 1.08
2018-09-30 2.79 2.00 1.16
2018-06-30 1.64 1.10 0.48
2018-03-31 1.64 0.35 0.45
2017-12-31 2.06 0.00 0.30
2017-09-30 -0.19 2.70 0.51
2017-06-30 1.59 2.00 0.30
2017-03-31 0.64 1.30 0.68
2016-12-31 3.44 0.00 0.11
2016-09-30 0.43 0.00 0.73
2016-06-30 -0.98 0.00 0.77
2016-03-31 -12.85 0.00 1.54
2015-12-31 1.59 3.11 0.53
2015-09-30 0.83 2.86 0.60
2015-06-30 0.81 2.26 0.55
2015-03-31 -0.08 0.00 0.61
2014-12-31 0.32 0.00 1.11
2014-09-30 4.10 0.00 0.47
2014-06-30 4.58 0.00 0.75
2014-03-31 0.60 0.00 0.99
2013-12-31 0.72 0.00 2.24
2013-09-30 0.54 0.00 1.79
2013-06-30 3.52 0.00 0.65
2013-03-31 5.22 0.00 1.91
2012-12-31 3.18 0.00 0.65
2012-09-30 5.15 0.00 2.38
2012-06-30 6.67 0.00 4.29
  • International Stem Cell's level of debt (72.6%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0% vs 72.6% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • International Stem Cell has less than a year of cash runway based on current free cash flow.
  • International Stem Cell has less than a year of cash runway if free cash flow continues to reduce at historical rates of -39.9% each year.
X
Financial health checks
We assess International Stem Cell's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. International Stem Cell has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is International Stem Cell's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from International Stem Cell dividends. Estimated to be 0% next year.
If you bought $2,000 of International Stem Cell shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate International Stem Cell's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate International Stem Cell's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
OTCPK:ISCO Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 19 Stocks 2.4%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2005 Stocks 2.5%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

OTCPK:ISCO Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as International Stem Cell has not reported any payouts.
  • Unable to verify if International Stem Cell's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of International Stem Cell's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as International Stem Cell has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of International Stem Cell's dividends in 3 years as they are not expected to pay a notable one for United States of America.
X
Income/ dividend checks
We assess International Stem Cell's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can International Stem Cell afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. International Stem Cell has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of International Stem Cell's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Andrey Semechkin
COMPENSATION $420,457
AGE 58
TENURE AS CEO 9.5 years
CEO Bio

Prof. Dr. Andrey Semechkin, Ph.D., has been the Chief Executive Officer of International Stem Cell Corporation since November 15, 2009. Prof. Dr. Semechkin is the Owner of AR Partners, LLC. Prof. Dr. Semechkin served as President of International Stem Cell Corporation until October 6, 2011. He served as Executive Vice President of Strategy and Science of International Stem Cell Corporation. Prof. Dr. Semechkin served as an Executive Vice President of International Stem Cell Corporation since July 2009. He also served as the Chief Business Officer at International Stem Cell Corporation. He has been Co-Chairman at International Stem Cell Corporation since October 6, 2011 and has been its Director since December 31, 2008. He is responsible for developing the overall business strategy, tracking and allocating International Stem's resources, overseeing the creation and implementation of personnel policy, defining target markets, identifying and developing new business opportunities and developing international business opportunities. Since 2004 he has been the Deputy Director of the Institute of System Analysis of the Russian Academy of Sciences since 2004. Prof. Dr. Semechkin has over 20 years of experience in the creation and managing of holding business structures in different industry and scientific sectors. He is the Chairman of X-Master, Inc. Prof. Dr. Semetchkine was awarded the Russian Government Award in Science and Technology in 2006. He is a specialist in system analysis, strategic planning and corporate management and the author of several scientific books. He is a member of the Russian Academy of Sciences.

CEO Compensation
  • Andrey's compensation has increased whilst company is loss making.
  • Andrey's remuneration is about average for companies of similar size in United States of America.
Management Team

Andrey Semechkin

TITLE
Co-Chairman & CEO
COMPENSATION
$420K
AGE
58
TENURE
9.5 yrs

Sophia Garnette

TITLE
VP of Legal Affairs & Operations
COMPENSATION
$457K
AGE
34

Russell Kern

TITLE
Executive VP
COMPENSATION
$326K
AGE
32
TENURE
5.9 yrs

Francisco Bustamante

TITLE
President of Lifeline Cell Technology LLC
Board of Directors Tenure

Average tenure and age of the International Stem Cell board of directors in years:

9.1
Average Tenure
66
Average Age
  • The tenure for the International Stem Cell board of directors is about average.
Board of Directors

Don Wright

TITLE
Co-Chairman
COMPENSATION
$159K
AGE
66

Andrey Semechkin

TITLE
Co-Chairman & CEO
COMPENSATION
$420K
AGE
58
TENURE
7.6 yrs

Kenneth Aldrich

TITLE
Co-Founder & Chairman Emeritus
COMPENSATION
$1M
AGE
79
TENURE
7.2 yrs

Russell Kern

TITLE
Executive VP
COMPENSATION
$326K
AGE
32
TENURE
10.6 yrs

Paul Maier

TITLE
Independent Director
COMPENSATION
$101K
AGE
70
TENURE
11.8 yrs

Elena Revazova

TITLE
Member of Scientific Advisory Board

Hans-Dieter Volk

TITLE
Member of Scientific Advisory Board

Matthias von Herrath

TITLE
Member of Scientific Advisory Board

Michael Kalichman

TITLE
Member of Scientific Advisory Board

Evan Snyder

TITLE
Member of Scientific Advisory Board
Who owns this company?
Recent Insider Trading
  • International Stem Cell insiders have only sold shares in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
22. Apr 19 Sell Paul Maier Individual 18. Apr 19 18. Apr 19 -1,350 $1.25 $-1,681
22. Jan 19 Buy Andrey Semechkin Individual 21. Jan 19 21. Jan 19 599,222 $1.75 $1,048,639
X
Management checks
We assess International Stem Cell's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. International Stem Cell has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

International Stem Cell Corporation focuses on the development of therapeutic and biomedical products worldwide. The company’s products are based on human parthenogenetic stem cells, a proprietary type of pluripotent stem cell. It develops various cell types, including neural stem cells for the treatment of Parkinson’s disease and other central nervous system disorders; liver cells to treat various congenital and acquired liver diseases; and islet cells for the treatment of diabetes. The company also develops, manufactures, and markets skincare products and human cell culture products. Its human cell culture products include human skin cells and reagents for the study of skin disease, toxicology, or wound healing; human cells from the heart and blood vessels, and reagents to study cardiovascular disease and cancer; human bronchial and tracheal cell lines for the study of toxicity, cystic fibrosis, asthma, and pathogenesis; and human mammary epithelial cell lines for the study of breast cancer, three dimensional culture, and carcinogen screening. The company’s human cell culture products also comprise adult stem cells and reagents for regenerative medicine; human prostate cells and specialized medium to study prostate disease; human renal and bladder cells and media to study renal and bladder diseases; human corneal cells and media for the study of corneal disease; human female reproductive system cells for the study of cellular physiology; human skeletal muscle cells for the study of biology, diabetes, insulin receptor studies, muscle metabolism, muscle tissue repair, and myotube development; and other cell culture reagents and supplements for the growth, staining, and freezing of human cells. It sells skincare products through a Website and professional channels; and human cell culture products through its sales force, OEM partners, and brand distributors. The company was founded in 2001 and is headquartered in Carlsbad, California.

Details
Name: International Stem Cell Corporation
ISCO
Exchange: OTCPK
Founded: 2001
$6,779,774
7,533,083
Website: http://www.internationalstemcell.com
Address: International Stem Cell Corporation
5950 Priestly Drive,
Carlsbad,
California, 92008,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OTCPK ISCO Common Stock Pink Sheets LLC US USD 09. Jan 2007
Number of employees
Current staff
Staff numbers
49
International Stem Cell employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/23 05:01
End of day share price update: 2019/05/22 00:00
Last estimates confirmation: 2019/05/02
Last earnings filing: 2019/05/15
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.